CA2850367C - Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders - Google Patents

Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders Download PDF

Info

Publication number
CA2850367C
CA2850367C CA2850367A CA2850367A CA2850367C CA 2850367 C CA2850367 C CA 2850367C CA 2850367 A CA2850367 A CA 2850367A CA 2850367 A CA2850367 A CA 2850367A CA 2850367 C CA2850367 C CA 2850367C
Authority
CA
Canada
Prior art keywords
compositions
derivatives
methods
uridine diphosphate
neurodegenerative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2850367A
Other languages
English (en)
French (fr)
Other versions
CA2850367A1 (en
Inventor
Philip Haydon
Jinbo Lee
Jinghui DONG
Stephen Moss
Raquel REVILLA-SANCHEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of CA2850367A1 publication Critical patent/CA2850367A1/en
Application granted granted Critical
Publication of CA2850367C publication Critical patent/CA2850367C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2850367A 2011-09-30 2012-09-28 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders Expired - Fee Related CA2850367C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541919P 2011-09-30 2011-09-30
US61/541,919 2011-09-30
PCT/US2012/058080 WO2013049686A1 (en) 2011-09-30 2012-09-28 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
CA2850367A1 CA2850367A1 (en) 2013-04-04
CA2850367C true CA2850367C (en) 2021-06-01

Family

ID=47996472

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2850367A Expired - Fee Related CA2850367C (en) 2011-09-30 2012-09-28 Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders

Country Status (9)

Country Link
US (6) US8598141B2 (enExample)
EP (1) EP2760858B1 (enExample)
JP (1) JP6162125B2 (enExample)
CN (2) CN103906745B (enExample)
AU (1) AU2012315671B2 (enExample)
CA (1) CA2850367C (enExample)
IL (1) IL231787A (enExample)
IN (1) IN2014CN03043A (enExample)
WO (1) WO2013049686A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6162125B2 (ja) * 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
US9163055B2 (en) * 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
PL2968385T3 (pl) * 2013-03-13 2019-05-31 Univ Tufts Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
EP3286172B1 (en) 2015-04-23 2019-06-12 Constellation Pharmaceuticals, Inc. Lsd1 inhibitors and uses thereof
EA201792261A1 (ru) 2015-05-29 2018-04-30 Зе Боард Оф Трастис Оф Зе Лилэнд Стэнфорд Джуниор Юниверсити Нуклеозидные вещества для уменьшения вредной активности генов, содержащих удлиненные нуклеотидные повторы
EP3515447A4 (en) * 2016-09-26 2020-05-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
LT3532459T (lt) 2016-10-26 2023-11-10 Constellation Pharmaceuticals, Inc. Lsd1 inhibitoriai ir jų medicininis panaudojimas
US20220241311A1 (en) * 2018-06-14 2022-08-04 Mayo Foundation For Medical Education And Research Methods and materials for treating glycosylation disorders
US20230165885A1 (en) * 2020-03-24 2023-06-01 Gliaguard, Inc. Treatment of eye disorders with uridine phosphate derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0621073B2 (ja) 1986-03-06 1994-03-23 日水製薬株式会社 中枢抑制剤
JP3032053B2 (ja) 1991-09-06 2000-04-10 日水製薬株式会社 ウリジン誘導体及びこれを含有する医薬
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
BR9811612A (pt) 1997-08-29 2000-08-08 Univ North Carolina Uso de 5' -difosfato de uridina e similares para tratamento de doenças pulmonares
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
DK1870103T3 (da) 1998-07-31 2010-01-11 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin i behandling af hukommelsesforsstyrrelse
US20060069061A1 (en) 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US20050203053A1 (en) 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US20070004670A1 (en) 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US20050074819A1 (en) * 2003-10-01 2005-04-07 Japan Health Sciences Foundation Screening method of drug for treatment of neuropathic pain
WO2005122767A1 (en) 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7851456B2 (en) 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
JP5513135B2 (ja) 2007-03-19 2014-06-04 カスケード プロドラッグ インコーポレイテッド マンニッヒ塩基ｎ−オキシド薬物
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2010039548A2 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
EP2646449B1 (en) 2010-12-01 2015-08-19 Bar-Ilan University Uridine di- or tri-phosphate derivatives and uses thereof
JP6162125B2 (ja) * 2011-09-30 2017-07-12 タフツ・ユニバーシティ 神経変性障害を処置するためのウリジン二リン酸誘導体、組成物および方法
US9163055B2 (en) * 2012-09-28 2015-10-20 Tufts University Methods for treating glaucoma using uridine diphosphate derivatives
US10138265B2 (en) 2013-03-13 2018-11-27 Tufts University Uridine nucleoside derivatives, compositions and methods of use
PL2968385T3 (pl) * 2013-03-13 2019-05-31 Univ Tufts Pochodne nukleozydów urydynowych, kompozycje i sposoby zastosowania

Also Published As

Publication number Publication date
US20190309009A1 (en) 2019-10-10
US20160318968A1 (en) 2016-11-03
CN107353316A (zh) 2017-11-17
US20210347807A1 (en) 2021-11-11
CN107353316B (zh) 2020-08-18
CN103906745A (zh) 2014-07-02
IL231787A0 (en) 2014-05-28
US20150045319A1 (en) 2015-02-12
US8598141B2 (en) 2013-12-03
US11072627B2 (en) 2021-07-27
JP6162125B2 (ja) 2017-07-12
JP2014528418A (ja) 2014-10-27
EP2760858A4 (en) 2015-04-22
AU2012315671A1 (en) 2014-04-17
CN103906745B (zh) 2017-08-25
IL231787A (en) 2017-05-29
WO2013049686A1 (en) 2013-04-04
US8785620B2 (en) 2014-07-22
EP2760858A1 (en) 2014-08-06
AU2012315671B2 (en) 2017-07-20
US20130252919A1 (en) 2013-09-26
US20140066613A1 (en) 2014-03-06
EP2760858B1 (en) 2018-08-08
IN2014CN03043A (enExample) 2015-07-03
US9227993B2 (en) 2016-01-05
CA2850367A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
IN2014CN03043A (enExample)
SA518391477B1 (ar) أملاح فالبينازين وصور متعددة الشكل البلوري منها
WO2014037416A3 (en) Compositions for treating parkinson's disease
MY178156A (en) Compounds and their use as bace inhibitors
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
MX2009008531A (es) Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
EA034135B9 (ru) Фармацевтические композиции на основе производных уридиновых нуклеозидов в качестве агонистов pyрецепторов
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
MX2009004908A (es) Compuestos quimicos.
MX2009010407A (es) Derivados fluorados de deferiprona.
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
MY152387A (en) Preparation and therapeutic applications of (2s,3r)-n-2((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl-3,5-difluorobenzamide
MX2015001917A (es) Composiciones farmaceuticas de memantina.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
PH12013501321B1 (en) Phenoxymethyl heterocyclic compounds
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
CL2014000119A1 (es) Sal de (r)-3-(6-(4-metilfenil)-piridin-3-iloxi)-1-aza-biciclo[2.2.2]octano; composicion farmaceutica; metodo de preparacion; proceso de prodcucion de la sal y sus precursores; y metodo para prevencion, tratamiento y/o retraso de la progresion de una enfermedad o condicion tal como trastornos psiquiatricos o neurodegenerativos.
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
WO2014082738A8 (en) Heteroquinoline-3-carboxamides as kcnq2/3 modulators
WO2014014794A3 (en) Mineralocorticoid receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170824

MKLA Lapsed

Effective date: 20220928